180 related articles for article (PubMed ID: 11640868)
1. Myeloproliferative disorders.
Bench AJ; Cross NC; Huntly BJ; Nacheva EP; Green AR
Best Pract Res Clin Haematol; 2001 Sep; 14(3):531-51. PubMed ID: 11640868
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics and cytogenetics of myeloproliferative disorders.
Bench AJ; Nacheva EP; Champion KM; Green AR
Baillieres Clin Haematol; 1998 Dec; 11(4):819-48. PubMed ID: 10640219
[TBL] [Abstract][Full Text] [Related]
4. Karyotype and molecular cytogenetic studies in polycythemia vera.
Andrieux JL; Demory JL
Curr Hematol Rep; 2005 May; 4(3):224-9. PubMed ID: 15865876
[TBL] [Abstract][Full Text] [Related]
5. Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders.
Panani AD
In Vivo; 2007; 21(5):867-70. PubMed ID: 18019426
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
[TBL] [Abstract][Full Text] [Related]
7. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
8. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
9. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.
Mertens F; Johansson B; Heim S; Kristoffersson U; Mitelman F
Leukemia; 1991 Mar; 5(3):214-20. PubMed ID: 2013980
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
11. [Karyotyping in chronic myeloproliferative syndrome (except chronic myeloid leukemia)].
Lessard M
Pathol Biol (Paris); 1982 Nov; 30(9):759-65. PubMed ID: 6760079
[TBL] [Abstract][Full Text] [Related]
12. 8p11 myeloproliferative syndrome: a review.
Jackson CC; Medeiros LJ; Miranda RN
Hum Pathol; 2010 Apr; 41(4):461-76. PubMed ID: 20226962
[TBL] [Abstract][Full Text] [Related]
13. Conventional cytogenetics in myelofibrosis: literature review and discussion.
Hussein K; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
16. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.
Reilly JT
Semin Oncol; 2005 Aug; 32(4):359-64. PubMed ID: 16202681
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.
Kralovics R; Skoda RC
Blood Rev; 2005 Jan; 19(1):1-13. PubMed ID: 15572213
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
20. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]